Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of lowgrade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) re
โฆ LIBER โฆ
Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients
โ Scribed by Olga A. Gra; Andrey S. Glotov; Eugene A. Nikitin; Oleg S. Glotov; Viktoria E. Kuznetsova; Alexander V. Chudinov; Andrey B. Sudarikov; Tatyana V. Nasedkina
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 193 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Tumor lysis syndrome occurring after the
โ
Yang, Honghao; Rosove, Michael H.; Figlin, Robert A.
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 27 KB
๐ 1 views
The effect of in vitro irradiation on mi
โ
Samuel Rotstein; Edward Baral; Henric Blomgren; Bo Johansson
๐
Article
๐
1982
๐
John Wiley and Sons
๐
English
โ 381 KB
๐ 2 views
Blood lymphocytes from 20 untreated patients with Hodgkin's disease were compared with those of 20 untreated patients with non-Hodgkin's lymphoma with regard to the responsiveness of the cells to PHA and ConA following exposure to varying doses of ionizing radiation in vitro. Lymphocytes from 19 of